OXSQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient trader. Price is pushing into nearby resistance (1.95) without supportive proprietary buy signals, and the probabilistic pattern signal points to more downside over the next week/month. I would avoid new entries here (or trim/exit if already holding) and only reconsider on a pullback closer to support (1.83–1.89) with improving momentum/volume.
Pre-market at ~1.949 is effectively testing R1 (1.952), a near-term ceiling. MACD histogram is positive and expanding (bullish momentum), but RSI(6) is ~69—near the overbought threshold—suggesting short-term upside may be limited right at resistance. Moving averages are converging, which often precedes a larger move but does not confirm direction. Key levels: Pivot 1.891; Support S1 1.83 (then S2 1.792); Resistance R1 1.952 (then R2 1.99). Pattern-based outlook provided is mildly positive for 1 day (+0.48%) but negative for 1 week (-3.36%) and 1 month (-7.07%), which is unfavorable for an impatient entry.
Intellectia Proprietary Trading Signals
MACD momentum is improving (positive and expanding histogram). Options open interest is strongly call-skewed (bullish positioning). Next earnings date is scheduled (2026-02-27 pre-market), which can become a volatility catalyst if expectations shift.
with RSI(
near 69, increasing the odds of a short-term stall/pullback. No supportive Intellectia buy signals (AI Stock Picker/SwingMax). Pattern-based forward view projects downside over the next week and month (-3.36% / -7.07%). No news in the past week—no clear near-term positive catalyst. Options IV is extremely elevated, implying the market is pricing risk (and often coincides with unstable price action).
Latest reported quarter: 2025/Q3. Revenue fell to 2,709,367 (-17.38% YoY), showing top-line weakness. Net income improved YoY (loss narrowed to -2,092,163, +139.23% YoY) and EPS improved to -0.03 (+200% YoY), indicating better profitability versus last year, but results remain negative overall and the revenue decline is a headwind.
No analyst rating/price target trend data was provided, so a Wall Street pros/cons consensus view cannot be confirmed from this dataset. From the available fundamentals/price action alone: Pros—improving EPS/loss trend and bullish call OI skew. Cons—declining revenue, lack of fresh catalysts/news, and price pressing resistance without proprietary buy signals.
